Literature DB >> 29710121

Association of Retinal Ganglion Cell Layer Thickness With Future Disease Activity in Patients With Clinically Isolated Syndrome.

Hanna G Zimmermann1, Benjamin Knier2,3, Timm Oberwahrenbrock1, Janina Behrens1, Catherina Pfuhl4, Lilian Aly2,3, Miriam Kaminski2, Muna-Miriam Hoshi2, Svenja Specovius1, René M Giess1, Michael Scheel1, Mark Mühlau2,5, Judith Bellmann-Strobl1,6, Klemens Ruprecht4, Bernhard Hemmer2,7, Thomas Korn2,3,7, Friedemann Paul1,4,6, Alexander U Brandt1.   

Abstract

Importance: Clinically isolated syndrome (CIS) describes a first clinical incident suggestive of multiple sclerosis (MS). Identifying patients with CIS who have a high risk of future disease activity and subsequent MS diagnosis is crucial for patient monitoring and the initiation of disease-modifying therapy. Objective: To investigate the association of retinal optical coherence tomography (OCT) results with future disease activity in patients with CIS. Design, Setting, and Participants: This prospective, longitudinal cohort study took place between January 2011 and May 2017 at 2 German tertiary referral centers. A total of 179 patients with CIS were screened (80 in Berlin and 99 in Munich). Patients underwent neurological examination, magnetic resonance imaging (MRI), and OCT. Only eyes with no previous optic neuritis were considered for OCT analysis. Main Outcomes and Measures: The primary outcome was not meeting the no evidence of disease activity (NEDA-3) criteria; secondary outcomes were MS diagnosis (by the 2010 McDonald criteria) and worsening of disability. The primary measure was OCT-derived ganglion cell and inner plexiform layer thickness; the secondary measures included peripapillary retinal nerve fiber layer thickness, inner nuclear layer thickness, and MRI-derived T2-weighted lesions.
Results: A total of 97 of the 179 screened patients (54.2%) were enrolled in the study at a median of 93 (interquartile range [IQR], 62-161) days after a first demyelinating event. The median follow-up duration (Kaplan-Meier survival time) was 729 (IQR, 664-903) days. Of 97 patients with CIS (mean age 33.6 [7.9] years; 61 [62.9%] female), 58 (59%) did not meet NEDA-3 criteria during the follow-up period. A Kaplan-Meier analysis showed a significant probability difference in not meeting NEDA-3 criteria by ganglion cell and inner plexiform later thickness (thinnest vs thickest tertile: hazard ratio [HR], 3.33 [95% CI, 1.70-6.55; P < .001; log-rank P = .001). A follow-up diagnosis of MS was more likely for patients with low ganglion cell and inner plexiform layer thickness (thinnest vs thickest tertile: HR, 4.05 [95% CI, 1.93-8.50]; P < .001). Low peripapillary retinal nerve fiber layer thickness likewise indicated risk of not meeting NEDA-3 criteria (thinnest vs thickest tertile: HR, 2.46 [95% CI, 1.29-4.66]; P = .01; log-rank P = .02). Inner nuclear layer thickness and T2-weighted lesion count were not associated with not meeting NEDA-3 criteria. Conclusions and Relevance: Retinal ganglion cell and inner plexiform layer thickness might prove a valuable imaging marker for anticipating future disease activity and diagnosis of MS in patients with CIS, which can potentially support patient monitoring and initiation of disease-modifying therapy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29710121      PMCID: PMC6143115          DOI: 10.1001/jamaneurol.2018.1011

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  44 in total

1.  Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis.

Authors:  Iñigo Gabilondo; Elena H Martínez-Lapiscina; Eloy Martínez-Heras; Elena Fraga-Pumar; Sara Llufriu; Santiago Ortiz; Santiago Bullich; Maria Sepulveda; Carles Falcon; Joan Berenguer; Albert Saiz; Bernardo Sanchez-Dalmau; Pablo Villoslada
Journal:  Ann Neurol       Date:  2014-01-02       Impact factor: 10.422

2.  Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome.

Authors:  W J Brownlee; D R Altmann; P Alves Da Mota; J K Swanton; K A Miszkiel; Cam Gandini Wheeler-Kingshott; O Ciccarelli; D H Miller
Journal:  Mult Scler       Date:  2016-08-06       Impact factor: 6.312

3.  Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.

Authors:  J Kuhle; G Disanto; R Dobson; R Adiutori; L Bianchi; J Topping; J P Bestwick; U-C Meier; M Marta; G Dalla Costa; T Runia; E Evdoshenko; N Lazareva; E Thouvenot; P Iaffaldano; V Direnzo; M Khademi; F Piehl; M Comabella; M Sombekke; J Killestein; H Hegen; S Rauch; S D'Alfonso; J C Alvarez-Cermeño; P Kleinová; D Horáková; R Roesler; F Lauda; S Llufriu; T Avsar; U Uygunoglu; A Altintas; S Saip; T Menge; C Rajda; R Bergamaschi; N Moll; M Khalil; R Marignier; I Dujmovic; H Larsson; C Malmestrom; E Scarpini; C Fenoglio; S Wergeland; A Laroni; V Annibali; S Romano; A D Martínez; A Carra; M Salvetti; A Uccelli; Ø Torkildsen; K M Myhr; D Galimberti; K Rejdak; J Lycke; J L Frederiksen; J Drulovic; C Confavreux; D Brassat; C Enzinger; S Fuchs; I Bosca; J Pelletier; C Picard; E Colombo; D Franciotta; T Derfuss; Rlp Lindberg; Ö Yaldizli; L Vécsei; B C Kieseier; H P Hartung; P Villoslada; A Siva; A Saiz; H Tumani; E Havrdová; L M Villar; M Leone; N Barizzone; F Deisenhammer; C Teunissen; X Montalban; M Tintoré; T Olsson; M Trojano; S Lehmann; G Castelnovo; S Lapin; R Hintzen; L Kappos; R Furlan; V Martinelli; G Comi; S V Ramagopalan; G Giovannoni
Journal:  Mult Scler       Date:  2015-02-13       Impact factor: 6.312

4.  Defining reliable disability outcomes in multiple sclerosis.

Authors:  Tomas Kalincik; Gary Cutter; Tim Spelman; Vilija Jokubaitis; Eva Havrdova; Dana Horakova; Maria Trojano; Guillermo Izquierdo; Marc Girard; Pierre Duquette; Alexandre Prat; Alessandra Lugaresi; Francois Grand'Maison; Pierre Grammond; Raymond Hupperts; Celia Oreja-Guevara; Cavit Boz; Eugenio Pucci; Roberto Bergamaschi; Jeannette Lechner-Scott; Raed Alroughani; Vincent Van Pesch; Gerardo Iuliano; Ricardo Fernandez-Bolaños; Cristina Ramo; Murat Terzi; Mark Slee; Daniele Spitaleri; Freek Verheul; Edgardo Cristiano; José Luis Sánchez-Menoyo; Marcela Fiol; Orla Gray; Jose Antonio Cabrera-Gomez; Michael Barnett; Helmut Butzkueven
Journal:  Brain       Date:  2015-09-10       Impact factor: 13.501

5.  Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study.

Authors:  Shiv Saidha; Elias S Sotirchos; Mohamed A Ibrahim; Ciprian M Crainiceanu; Jeffrey M Gelfand; Yasir J Sepah; John N Ratchford; Jiwon Oh; Michaela A Seigo; Scott D Newsome; Laura J Balcer; Elliot M Frohman; Ari J Green; Quan D Nguyen; Peter A Calabresi
Journal:  Lancet Neurol       Date:  2012-10-04       Impact factor: 44.182

6.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2008-10-25       Impact factor: 79.321

Review 7.  Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography.

Authors:  J L Bennett; J de Seze; M Lana-Peixoto; J Palace; A Waldman; S Schippling; S Tenembaum; B Banwell; B Greenberg; M Levy; K Fujihara; K H Chan; H J Kim; N Asgari; D K Sato; A Saiz; J Wuerfel; H Zimmermann; A Green; P Villoslada; F Paul
Journal:  Mult Scler       Date:  2015-02-06       Impact factor: 6.312

8.  Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis.

Authors:  Imke Metz; Tim Beißbarth; David Ellenberger; Florence Pache; Lidia Stork; Marius Ringelstein; Orhan Aktas; Sven Jarius; Brigitte Wildemann; Hassan Dihazi; Tim Friede; Wolfgang Brück; Klemens Ruprecht; Friedemann Paul
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-02-02

9.  Microstructural visual system changes in AQP4-antibody-seropositive NMOSD.

Authors:  Frederike C Oertel; Joseph Kuchling; Hanna Zimmermann; Claudia Chien; Felix Schmidt; Benjamin Knier; Judith Bellmann-Strobl; Thomas Korn; Michael Scheel; Alexander Klistorner; Klemens Ruprecht; Friedemann Paul; Alexander U Brandt
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-02-22

10.  The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.

Authors:  Ludwig Kappos; Gilles Edan; Mark S Freedman; Xavier Montalbán; Hans-Peter Hartung; Bernhard Hemmer; Edward J Fox; Frederik Barkhof; Sven Schippling; Andrea Schulze; Dirk Pleimes; Christoph Pohl; Rupert Sandbrink; Gustavo Suarez; Eva-Maria Wicklein
Journal:  Neurology       Date:  2016-08-10       Impact factor: 9.910

View more
  14 in total

1.  Retinal Tissue Perfusion in Patients with Multiple Sclerosis.

Authors:  Yi Liu; Silvia Delgado; Hong Jiang; Ying Lin; Jeffrey Hernandez; Yuqing Deng; Giovana Rosa Gameiro; Jianhua Wang
Journal:  Curr Eye Res       Date:  2019-05-15       Impact factor: 2.424

Review 2.  Multiple sclerosis.

Authors:  Massimo Filippi; Amit Bar-Or; Fredrik Piehl; Paolo Preziosa; Alessandra Solari; Sandra Vukusic; Maria A Rocca
Journal:  Nat Rev Dis Primers       Date:  2018-11-08       Impact factor: 52.329

3.  Retinal ganglion cell layer thickness and volume measured by OCT changes with age, sex, and axial length in a healthy population.

Authors:  Abbas Al-Hawasi; Neil Lagali
Journal:  BMC Ophthalmol       Date:  2022-06-24       Impact factor: 2.086

4.  Intraretinal Layer Segmentation Using Cascaded Compressed U-Nets.

Authors:  Sunil Kumar Yadav; Rahele Kafieh; Hanna Gwendolyn Zimmermann; Josef Kauer-Bonin; Kouros Nouri-Mahdavi; Vahid Mohammadzadeh; Lynn Shi; Ella Maria Kadas; Friedemann Paul; Seyedamirhosein Motamedi; Alexander Ulrich Brandt
Journal:  J Imaging       Date:  2022-05-17

5.  Prediction of high and low disease activity in early MS patients using multiple kernel learning identifies importance of lateral ventricle intensity.

Authors:  Claudia Chien; Moritz Seiler; Fabian Eitel; Tanja Schmitz-Hübsch; Friedemann Paul; Kerstin Ritter
Journal:  Mult Scler J Exp Transl Clin       Date:  2022-07-03

Review 6.  The International Multiple Sclerosis Visual System Consortium: Advancing Visual System Research in Multiple Sclerosis.

Authors:  Laura J Balcer; Lisanne J Balk; Alexander U Brandt; Peter A Calabresi; Elena H Martinez-Lapiscina; Rachel C Nolan; Friedemann Paul; Axel Petzold; Shiv Saidha
Journal:  J Neuroophthalmol       Date:  2018-12       Impact factor: 3.042

7.  Explorative study of emerging blood biomarkers in progressive multiple sclerosis (EmBioProMS): Design of a prospective observational multicentre pilot study.

Authors:  Ahmed Abdelhak; Andre Huss; Alexander Stahmann; Makbule Senel; Markus Krumbholz; Markus C Kowarik; Joachim Havla; Tania Kümpfel; Ingo Kleiter; Isabella Wüstinger; Uwe K Zettl; Margit Schwartz; Romy Roesler; Tim Friede; Albert C Ludolph; Ulf Ziemann; Hayrettin Tumani
Journal:  Contemp Clin Trials Commun       Date:  2020-05-19

8.  Evaluation of Retinal Layer Thickness Parameters as Biomarkers in a Real-World Multiple Sclerosis Cohort.

Authors:  Natascha Schurz; Lydia Sariaslani; Patrick Altmann; Fritz Leutmezer; Christoph Mitsch; Berthold Pemp; Paulus Rommer; Tobias Zrzavy; Thomas Berger; Gabriel Bsteh
Journal:  Eye Brain       Date:  2021-03-12

9.  Optic Nerve Topography in Multiple Sclerosis Diagnosis: The Utility of Visual Evoked Potentials.

Authors:  Angela Vidal-Jordana; Alex Rovira; Georgina Arrambide; Susana Otero-Romero; Jordi Río; Manuel Comabella; Carlos Nos; Joaquin Castilló; Ingrid Galan; Sergio Cabello; Dulce Moncho; Kimia Rahnama; Vanessa Thonon; Breogan Rodríguez-Acevedo; Ana Zabalza; Luciana Midaglia; Cristina Auger; Jaume Sastre-Garriga; Xavier Montalban; Mar Tintoré
Journal:  Neurology       Date:  2020-12-16       Impact factor: 9.910

10.  Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study.

Authors:  Stefan Bittner; Falk Steffen; Timo Uphaus; Muthuraman Muthuraman; Vinzenz Fleischer; Anke Salmen; Felix Luessi; Achim Berthele; Luisa Klotz; Sven G Meuth; Antonios Bayas; Friedemann Paul; Hans-Peter Hartung; Ralf Linker; Christoph Heesen; Martin Stangel; Brigitte Wildemann; Florian Then Bergh; Björn Tackenberg; Tania Kuempfel; Frank Weber; Uwe K Zettl; Ulf Ziemann; Hayrettin Tumani; Sergiu Groppa; Mark Mühlau; Carsten Lukas; Bernhard Hemmer; Heinz Wiendl; Ralf Gold; Frauke Zipp
Journal:  EBioMedicine       Date:  2020-05-24       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.